Intarcia Therapeutics Completes $210M in Financings

Intarcia Therapeutics Inc., a privately held biotech company, has completed two financings totaling $210 million. The financing includes $160 million in preferred stock private placement and $50 million in debt financing. Investors include New Enterprise Associates, New Leaf Venture Partners, Venrock, The Baupost Group, and Farallon Capital Management.

North AmericaUSBriefs